BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2012

Feb 23, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2012-02-22

Reporting Person: Babu Yarlagadda S (VP Drug Discovery)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-02-22	Common Stock	M	5865	$1.18	Acquired	58603	Direct
2012-02-22	Common Stock	M	1226	$1.04	Acquired	59829	Direct
2012-02-22	Common Stock	M	23821	$1.20	Acquired	83650	Direct
2012-02-22	Common Stock	S	30912	$4.22	Disposed	52738	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-02-22	Emp. Stock Option (Right to Buy)	$1.18	M	5865	Disposed	2012-08-05	Common Stock (5865)	Direct
2012-02-22	Emp. Stock Option (Right to Buy)	$1.04	M	1226	Disposed	2012-12-11	Common Stock (1226)	Direct
2012-02-22	Emp. Stock Option (Right to Buy)	$1.20	M	23821	Disposed	2019-03-02	Common Stock (23821)	Direct

Footnotes

F1: The price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.18 to $4.26. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price.